Gelnique

Gelnique is a brand name of oxybutynin, approved by the FDA in the following formulation(s):

GELNIQUE (oxybutynin chloride - gel; transdermal)

• 
  Manufacturer: WATSON LABS
  
  Approval date: January 27, 2009
  
  Strength(s): 10%(100MG/PACKET) ^[RLD]

Has a generic version of Gelnique been approved?

No. There is currently no therapeutically equivalent version of Gelnique available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gelnique. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Compositions and methods for transdermal oxybutynin therapy
  Patent 7,029,694
  Issued: April 18, 2006
  Inventor(s): Ebert; Charles D. & Sanders; Steven W.
  Assignee(s): Watson Laboratories, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
    ✓ 
    Drug product
  
  



• 
  Compositions and methods for transdermal oxybutynin therapy
  Patent 7,179,483
  Issued: February 20, 2007
  Inventor(s): Ebert; Charles D. & Sanders; Steven W.
  Assignee(s): Watson Pharmaceuticals, Inc.
  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
  
  Patent expiration dates:
  
  
  • April 26, 2020
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 27, 2012 - NEW DOSAGE FORM
  
  

See also...

• Gelnique Consumer Information (Drugs.com)
• Gelnique Gel Consumer Information (Wolters Kluwer)
• Gelnique topical Consumer Information (Cerner Multum)
• Gelnique Advanced Consumer Information (Micromedex)
• Oxybutynin Consumer Information (Drugs.com)
• Oxybutynin Consumer Information (Wolters Kluwer)
• Oxybutynin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Oxybutynin Gel Consumer Information (Wolters Kluwer)
• Oxybutynin Syrup Consumer Information (Wolters Kluwer)
• Oxybutynin System Consumer Information (Wolters Kluwer)
• Oxybutynin Consumer Information (Cerner Multum)
• Oxybutynin topical Consumer Information (Cerner Multum)
• Oxybutynin transdermal Consumer Information (Cerner Multum)
• Oxybutynin Advanced Consumer Information (Micromedex)
• Oxybutynin Transdermal Advanced Consumer Information (Micromedex)
• Oxybutynin Chloride AHFS DI Monographs (ASHP)